Method: We searched electronic databases from inception until January 2024 for randomized controlled trials (RCTs) that analyzed the weight loss effect of GLP-1 receptor agonists in adolescents with obesity or overweight without diabetes mellitus. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.